Slco2b1 mRNA decreased to 52%, 58%, and 56% of control in the WT-NASH, O–/–-C, and O–/–-NASH groups, respectively. This evidence concerns the gene SLCO2B1 and metabolic dysfunction-associated steatohepatitis.